A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Juan J Rojas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Unit, Department of Pathology and Experimental Therapies, School of Medicine, University of Barcelona - UB, 08907 L'Hospitalet de Llobrega…. Hauptthemen laut MEDLINE: Vaccinia virus, Oncolytic Viruses, Oncolytic Virotherapy, Immunogenic Cell Death. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Government of Catalonia Agency for Administration of University and Research Grants, German Cancer Aid.
Abstract (Originalsprache)
Vaccinia viruses (VACVs) are versatile therapeutic agents and different features of various VACV strains allow for a broad range of therapeutic applications. Modified VACV Ankara (MVA) is a particularly altered VACV strain that is highly immunogenic, incapable of replicating in mammalian hosts, and broadly used as a safe vector for vaccination. Alternatively, Western Reserve (WR) or Copenhagen (Cop) are VACV strains that efficiently replicate in cancer cells and, therefore, are used to develop oncolytic viruses. However, the immune evasion capacity of WR or Cop hinders their ability to elicit antitumor immune responses, which is crucial for efficacy in the clinic. Here, we describe a new VACV strain named Immune-Oncolytic VACV Ankara (IOVA), which combines efficient replication in cancer cells with induction of immunogenic tumor cell death (ICD). IOVA was engineered from an MVA ancestor and shows superior cytotoxicity in tumor cells. In addition, the IOVA genome incorporates mutations that lead to massive fusogenesis of tumor cells, which contributes to improved antitumor effects. In syngeneic mouse tumor models, the induction of ICD results in robust antitumor immunity directed against tumor neo-epitopes and eradication of large established tumors. These data present IOVA as an improved immunotherapeutic oncolytic vector.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunology Unit, Department of Pathology and Experimental Therapies, School of Medicine, University of Barcelona - UB, 08907 L'Hospitalet de Llobregat, Spain; Immunity, Inflammation, and Cancer Group, Oncobell Program,…
- VIB Center for Inflammation Research, VIB, 9052 Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium.
- Division of Virology, Institute for Infection Medicine and Zoonoses, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleiβheim, Germany.
- Division of Virology, Institute for Infection Medicine and Zoonoses, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleiβheim, Germany; Institute of Virology, University of Veterinary Medicine Hannover, 3055…
- Department of Biomedical Molecular Biology, Ghent University, 9052 Ghent, Belgium; VIB Center for Medical Biotechnology, VIB, 9052 Ghent, Belgium; Department of Biochemistry and Microbiology, Ghent University, 9052 Ghen…
- Division of Virology, Institute for Infection Medicine and Zoonoses, Department of Veterinary Sciences, LMU Munich, 85764 Oberschleiβheim, Germany; German Center for Infection Research (DZIF), Partner Site Munich, 80539…
Förderung
- Ministerio de Ciencia e Innovación
- Government of Catalonia Agency for Administration of University and Research Grants
- German Cancer Aid
- Spanish Association Against Cancer Scientific Foundation
- Spain Ministry of Science and Innovation
Zitieren
APA
Rojas, J. J., Van Hoecke, L., Conesa, M., Bueno-Merino, C., Del Canizo, A., Riederer, S., Barcia, M., Brosinski, K., Lehmann, M. H., Volz, A., Saelens, X., & Sutter, G. (2024). A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.05.014
Vancouver
Rojas JJ, Van Hoecke L, Conesa M, Bueno-Merino C, Del Canizo A, Riederer S, et al. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.05.014
BibTeX
@article{Rojas2024,
author = {Rojas, Juan J and Van Hoecke, Lien and Conesa, Miquel and Bueno-Merino, Carmen and Del Canizo, Ana and Riederer, Stephanie and Barcia, Maria and Brosinski, Katrin and Lehmann, Michael H and Volz, Asisa and Saelens, Xavier and Sutter, Gerd},
title = {A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.05.014}
}
EUVIMED